- Home
- PAMT vs CBIO Comparison
PAMT vs CBIO Comparison
Compare PAMT & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- CBIO
- Stock Information
- Founded
- PAMT 1980
- CBIO 2003
- Country
- PAMT United States
- CBIO United States
- Employees
- PAMT N/A
- CBIO N/A
- Industry
- PAMT Trucking Freight/Courier Services
- CBIO
- Sector
- PAMT Industrials
- CBIO
- Exchange
- PAMT Nasdaq
- CBIO Nasdaq
- Market Cap
- PAMT 223.5M
- CBIO 218.2M
- IPO Year
- PAMT 1985
- CBIO N/A
- Fundamental
- Price
- PAMT $10.85
- CBIO $12.87
- Analyst Decision
- PAMT Hold
- CBIO Strong Buy
- Analyst Count
- PAMT 1
- CBIO 5
- Target Price
- PAMT $13.00
- CBIO $25.60
- AVG Volume (30 Days)
- PAMT 6.4K
- CBIO 120.1K
- Earning Date
- PAMT 10-28-2025
- CBIO 11-23-2025
- Dividend Yield
- PAMT N/A
- CBIO N/A
- EPS Growth
- PAMT N/A
- CBIO N/A
- EPS
- PAMT N/A
- CBIO N/A
- Revenue
- PAMT $623,270,000.00
- CBIO N/A
- Revenue This Year
- PAMT N/A
- CBIO N/A
- Revenue Next Year
- PAMT $12.19
- CBIO N/A
- P/E Ratio
- PAMT N/A
- CBIO N/A
- Revenue Growth
- PAMT N/A
- CBIO N/A
- 52 Week Low
- PAMT $10.51
- CBIO $9.81
- 52 Week High
- PAMT $23.70
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- PAMT 40.19
- CBIO 55.07
- Support Level
- PAMT $10.70
- CBIO $12.31
- Resistance Level
- PAMT $11.55
- CBIO $13.27
- Average True Range (ATR)
- PAMT 0.35
- CBIO 0.84
- MACD
- PAMT 0.02
- CBIO 0.16
- Stochastic Oscillator
- PAMT 28.57
- CBIO 88.44
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.